Bavarian Nordic

What Bavarian Nordic does

Bavarian Nordic A/S is a fully integrated, Denmark-based vaccine biotechnology company (Nasdaq Copenhagen: BAVA; ADR: BVNRY) that researches, develops, manufactures, and commercializes vaccines across two divisions: Public Preparedness and Travel Health. The Public Preparedness franchise is anchored by JYNNEOS/IMVANEX/IMVAMUNE, a non-replicating MVA-BN smallpox and mpox vaccine supplied to more than 70 countries and stockpiled by the U.S. Strategic National Stockpile (28 million doses manufactured), the European Commission/HERA, and national health agencies. The Travel Health franchise, significantly expanded by the 2023 acquisition of Emergent BioSolutions' travel health business (up to $380 million), includes Rabipur/RabAvert (rabies), Encepur (tick-borne encephalitis), Vivotif (typhoid), Vaxchora (cholera), and the newly approved Vimkunya (chikungunya, FDA/EMA/MHRA/Swissmedic approvals in 2025–2026).

The company's commercial moat rests on the proprietary MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) platform, which underpins both marketed and pipeline vaccines (including MVA-BN Filo for Janssen's Ebola regimen, MVA-BN WEV for equine encephalitis, RSV, and COVID-19 candidates), and on its own EU cGMP-compliant, FDA-inspected commercial-scale manufacturing facilities in Kvistgaard, Denmark and Bern, Switzerland. End-to-end manufacturing capabilities (including liquid and freeze-dried fill-and-finish) limit dependence on third-party contract manufacturers and underpin the 28% FY2025 EBITDA margin on DKK 6,244 million of revenue.

Bavarian Nordic makes money through four streams: government procurement of public preparedness vaccines under multi-year contracts (BARDA, HERA, DoD, Canada PHAC), commercial sales of travel vaccines through pharmacies and healthcare providers globally, contract manufacturing services for third-party pharma (notably Janssen for the Ebola vaccine regimen), and fully funded R&D contracts with governments (e.g., up to $83 million from the U.S. DoD for MVA-BN WEV). Approximately 1,861 employees support operations across Europe, North America, and emerging markets through both direct sales and channel partnerships such as Eurofarma (Brazil) and Serum Institute of India (chikungunya tech transfer). The company is in a period of transition following the failed November 2025 takeover attempt by Nordic Capital and Permira (DKK 250/share, ~$3.1 billion) and the announced departure of long-tenured CEO Paul Chaplin.

Name

Bavarian Nordic

Legal name

Bavarian Nordic A/S

Website

https://bavarian-nordic.com

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Bavarian Nordic is a Denmark-based, fully integrated vaccine biotech that develops and manufactures the MVA-BN-based smallpox/mpox vaccine (JYNNEOS) and a travel health portfolio (rabies, TBE, typhoid, cholera, chikungunya), supplying governments in 70+ countries and commercial distributors under multi-year procurement contracts.

Ownership category

akta.pro rank

Product category

Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA)

akta.pro secondary industries

Adult Vaccines (HLAIAEAB), Vaccine Cold Chain, Storage & Distribution (HLAIAEAK), Vaccine Procurement, Tendering & Immunization Supply Programs (HLAIAEAN), Immunization & Vaccine Delivery Programs (BPADAIAB)

Keywords

• Infectious disease vaccines
• Smallpox mpox vaccines
• Travel health vaccines
• Live virus vaccine platform
• Biopharmaceutical manufacturing

Headquarters

HQ city

Kvistgaard

HQ country

Denmark

HQ region

Europe

Offices13 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Public Preparedness Vaccines: Government procurement of smallpox/mpox vaccines (JYNNEOS/IMVANEX) for national stockpiles. Revenue driven by long-term contracts with U.S. BARDA, European HERA, and other government agencies. Includes ongoing COVID-19 vaccine development programs.
2. Travel Health Vaccines: Commercial sale of travel vaccines including Rabipur/RabAvert (rabies), Encepur (tick-borne encephalitis), Vivotif (typhoid), Vaxchora (cholera), and Vimkunya (chikungunya). Distributed through pharmacies and healthcare providers globally.
3. Contract Manufacturing: Manufacturing services for third-party vaccine producers including Janssen for Ebola vaccine (MVA-BN Filo). Revenue from process development and manufacturing services.
4. US Government R&D Contracts: Fully-funded development contracts with U.S. Department of Defense for equine encephalitis vaccine (up to USD 83 million). Includes Phase 2 development and options for Phase 3 preparation.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Bavarian Nordic develops, manufactures, and commercializes life-saving vaccines across two divisions: Public Preparedness (smallpox/mpox vaccines such as JYNNEOS/IMVANEX/IMVAMUNE sold to government stockpiles in 70+ countries) and Travel Health (rabies, tick-borne encephalitis, typhoid, cholera, and chikungunya vaccines sold through pharmacies and healthcare providers). The proprietary MVA-BN non-replicating live virus vaccine platform underpins both marketed products and pipeline candidates including equine encephalitis and influenza vaccines, manufactured at the company's own cGMP-compliant facilities in Denmark and Switzerland.

Product overview

Bavarian Nordic is a fully integrated global vaccine company with a diversified portfolio spanning two main divisions: Public Preparedness (smallpox/mpox vaccines) and Travel Health (rabies, tick-borne encephalitis, typhoid, cholera, and chikungunya vaccines). The company operates its own commercial-scale manufacturing facilities in Denmark and Switzerland, enabling end-to-end production from R&D through manufacturing and commercialization. Key products include JYNNEOS®/IMVANEX®/IMVAMUNE® for smallpox/mpox, Rabipur®/RabAvert® for rabies, Encepur® for tick-borne encephalitis, Vivotif® for typhoid, Vaxchora® for cholera, and Vimkunya® for chikungunya. The proprietary MVA-BN® platform technology serves as the foundation for both marketed products and pipeline candidates including MVA-BN WEV for equine encephalitis.

Differentiator

Problem solved

Functional benefit

Brands

• JYNNEOS: Smallpox/mpox vaccine marketed in the US
• IMVANEX
• IMVAMUNE
• MVA-BN
• Rabipur
• RabAvert
• Encepur
• Vivotif
• Vaxchora
• Vimkunya

Products and services

• JYNNEOS®/IMVANEX®/IMVAMUNE® FDA-approved non-replicating smallpox and mpox vaccine based on MVA-BN® platform technology, supplied to U.S. Strategic National Stockpile and governments in more than 70 countries for public health preparedness.
• Rabipur®/RabAvert® Market-leading rabies vaccine for pre- and post-exposure prophylaxis, acquired as part of the travel health business from Emergent BioSolutions.
• Encepur® Tick-borne encephalitis vaccine for travelers and endemic populations, acquired as part of the travel health business from Emergent BioSolutions.
• Vivotif® Typhoid vaccine for travelers to endemic regions, acquired as part of the travel health business from Emergent BioSolutions.
• Vaxchora® Cholera vaccine for travelers, approved and commercialized in multiple countries including Canada, acquired as part of the travel health business from Emergent BioSolutions.
• Vimkunya® Single-dose virus-like particle (VLP) chikungunya vaccine approved by FDA, European Commission, UK MHRA, and Swissmedic in 2025-2026 for individuals aged 12 and above. Addresses a disease that has caused outbreaks in over 110 countries.
• MVA-BN® WEV Multi-valent vaccine candidate in Phase 2 development against western, eastern, and Venezuelan equine encephalitis viruses. Fully funded under contracts with the U.S. government. No approved vaccines currently exist for these diseases.
• MVA-BN Filo (Ebola Vaccine - Janssen partnership) Licensed Ebola vaccine (MVA-BN Filo) produced for Janssen's Ebola vaccine regimen. Bavarian Nordic has manufactured 2 million doses as part of the partnership.

Quantifiable outcome

• Supplied vaccines to more than 70 countries
• +2 more outcomes

Named customers6 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core, minor and major.

• Serum Institute of IndiacoreStrategic or Co-development Partner · 11 March 2026Manufacturing agreement for chikungunya vaccine with full technology transfer enabling scaled production for future supply to endemic low- and middle-income countries. Builds on existing mpox vaccine license partnership. Replaced previous agreement with Biological E. Limited.
• NOFLU Consortium (EU Commission)minorStrategic or Co-development Partner · 25 February 2026Part of consortium awarded up to EUR 148 million European Commission contract to advance novel pandemic influenza vaccine (mRNA mucosal vaccine). Consortium includes Ethris, Evonik, NIVI Development, Statens Serum Institut, ECRAID, and VisMederi.
• EurofarmamajorChannel Partner/ Reseller/ Distributor · 1 January 2026Strategic partnership for distribution of vaccines in Brazil, expanding access in Latin American markets.
• European Health Emergency Response Authority (HERA)coreStrategic or Co-development Partner · 31 October 2025Joint procurement agreement with European Commission for up to 8 million doses of smallpox/mpox vaccine over four years, involving 20 European countries. Initial order of 750,000 doses for delivery in 2026.
• Africa CDCminorGTM or Marketing Partner · 1 October 2025Donation of 110,000 mpox vaccine doses to support outbreak response in Africa, with Uganda receiving part of the delivery. Total commitment of 165,000 doses.
• Emergent BioSolutionscoreStrategic or Co-development Partner · 15 February 2023Acquired Emergent BioSolutions' travel vaccines portfolio including typhoid, cholera, and chikungunya vaccines, along with manufacturing and development facilities. Transaction valued at up to $380 million including $270 million upfront payment. Approximately 280 employees transitioned to Bavarian Nordic.
• U.S. Department of DefensecoreStrategic or Co-development Partner · 23 December 2022Advanced development agreement for MVA-BN WEV equine encephalitis vaccine valued up to USD 83 million, with USD 55 million secured for Phase 2 development through 2026 plus USD 28 million options for Phase 3 preparation.
• Janssen Pharmaceuticals (Johnson & Johnson)majorStrategic or Co-development PartnerLicensed Ebola vaccine (MVA-BN Filo) partnership with Janssen. Bavarian Nordic has manufactured 2 million doses as part of Janssen's Ebola vaccine regimen. Also partners on RSV vaccine development.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Novavax: Vaccine specialist using a recombinant nanoparticle platform (Matrix-M), most exposed to public health preparedness and travel health. Comparable as a pure-play vaccine company focused on differentiated platform technology serving both government and commercial channels.
• Valneva: European specialty vaccine company with a competing chikungunya vaccine (IXCHIQ) plus travel vaccines (JE, cholera). Direct head-to-head competitor in chikungunya and adjacent travel health indications, also publicly listed with similar mid-cap profile.
• Emergent BioSolutions: U.S. biodefense and vaccine company that previously owned the travel health portfolio Bavarian Nordic acquired in 2023 for up to USD 380M. Directly comparable as a public health preparedness and vaccine manufacturer targeting government stockpiles (BARDA, SNS).

Broad incumbents

• GSK (Vaccines): Major vaccine incumbent with extensive travel and endemic vaccine franchises (hepatitis, typhoid, rabies) and a substantial biodefense/biopreparedness footprint. Competes for government preparedness contracts but as part of a diversified pharma portfolio.
• Sanofi Pasteur: Global vaccine division of Sanofi, one of the largest vaccine manufacturers worldwide with established travel vaccines (typhoid, rabies) and public health programs. Comparable in the overlap of public preparedness and travel health portfolios, but operates at much larger scale across many therapeutic areas.
• Merck & Co. Large pharmaceutical incumbent with the Ervebo Ebola vaccine regimen that competes with Bavarian Nordic's MVA-BN Filo component. Has substantial government contracting capability and biodefense R&D resources comparable to BARDA-funded programs.
• BioNTech: mRNA vaccine company with mpox, malaria, and infectious disease programs. Comparable in targeting emerging infectious disease preparedness but operates at much larger scale post-COVID and uses a different platform technology.

Others

• Serum Institute of India: World's largest vaccine manufacturer by volume and Bavarian Nordic's chikungunya manufacturing partner (technology transfer for LMIC supply). Functions both as a contract manufacturer for the chikungunya VLP and as a strategic ally enabling access to endemic markets that Bavarian Nordic does not directly serve.
• Dynavax Technologies: Vaccine-focused biotech with CpG 1018 adjuvant used in hepatitis B and pandemic influenza adjuvanted vaccines. Comparable as a public, vaccine-pure-play serving government preparedness channels, though focused on adjuvant technology rather than complete vaccine products.

Emerging players

• Moderna: mRNA vaccine company with mpox, RSV, and influenza programs that overlap with Bavarian Nordic's pipeline. Different platform (mRNA vs. MVA-BN) but competing for the same government preparedness contracts and adjuvant-naive traveler market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bavariannordic
• Xx.com/bavariannordic
• Facebookfacebook.com/bavariannordic

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries11 records

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bavarian Nordic